Section 7. Acute side effects and oncological emergencies

7.0 Early and Intermediate consequences of SACT, radiotherapy and surgery Understands the consequences of therapies, techniques and modalities used to treat CYP cancer and the appropriate assessment and management of treatment-related adverse effects. Provide relevant and timely information to enable CYP, families and carers to engage in clinical decision-making about their treatment and care	nurses provid CYP cancer of PICU, Practice	t-registration ling generalist are (e.g. A&E, nurses, general gy departments)	Unregistered Support Workers in specialist CYP cancer	Registrants providing specialist CYP cancer care (PTC and designated cancer specialist roles in POSCUs)						
Learning outcomes: Practitioners will be able to:	Pre-reg Children's Field	Registered Nurse	Health Care Assistant / support worker	Nursing Associate	Registered	Enhanced	Advanced	Consultant		
7.1 Identify the most common side effects of SACT, radiotherapy and cancer surgery.										
7.2 Explain treatment-related emergencies (including the potential for adverse reactions) and the signs and symptoms										
7.3 Discuss the management of side effects, including neutropenic sepsis, and the impact on CYP, families and carers										
7.4 Identify the evidence to reduce the risk of the acute toxicities of cancer treatments and discuss agents to minimise side effects e.g. antibiotics, antipyretics, analgesics, anti-emetics)										
7.5 Explain the role of supportive care and symptom management during cancer treatment.										
7.6 Understand the emotional and behavioural impact of steroids on children and young people within the whole family dynamic										
7.7 Understand that CYP, families and carers education about signs, symptoms and oncological emergencies must be developed over time, and can discuss how to achieve this.										
Practice competencies: Practitioners will be able to:	Pre-reg Children's Field	Registered Nurse	Health Care Assistant / support worker	Nursing Associate	Registered	Enhanced	Advanced	Consultant		
Across all modalities of treatment (N.B additional modalities specfic competencies in section	ons below)				°	-	•			
7.8 Identify patients at increased risk of adverse reactions										
7.9 Identify acute side effects and toxicities of cancer treatments: SACT, radiotherapy, and surgery										
7.10 Use evidence-based interventions to assess, prevent, recognise and assist in the management of emergencies caused by cancer treatment knowing when to refer to, and involve, other healthcare professionals										
7.11 Effectively utilise techniques and tools commonly used to identify deterioration (e.g. PEWS or SPOT, Neuro-Observations)										
7.12 Complete Telephone Triage using the defined helpline (specific competencies detailed in https://www.cclg.org.uk/triagetool)										
7.13 Locate appropriate policies, treatments and equipment to be used for supportive and emergency care										
7.14 Identify sources of information, provide and use appropriate educational material for CYP, families and carers on how to monitor and report signs of side effects and toxicities of cancer treatments.										

7.15	Relate clinical information (regarding side effects) in a way that is appropriate to the CYP, family and carers' understanding					
7.16	Educate CYP, families and carers on the practical skills required for effective treatment and interventions (e.g. use of thermometers, administration of medicines)					
7.17	Demonstrate ability to safely assess CYP, families and carers readiness for discharge and their understanding of side effects, emergencies, when and how to act (specific to their recent treatment modalities). Specifically includes CYP understanding why they should alert a responsible adult if they have symptoms.					
7.18	Show knowledge of blood values and their relevance in the management of side effects					
7.19	Contribute to the development of policies or guidelines to manage side effects, toxicities and oncological emergencies					
7.20	Maintain accurate and contemporaneous records of assessment and management of side effects, toxicities, and emergencies					
Extra	vasation, hypersensitivity and allergic reactions				 	
7.21	Recognise signs and symptoms of extravasation, hypersensitivity or allergic reaction					
7.22	Appropriately manage extravasation and infiltration, hypersensitivity or other adverse reaction as per local guidelines					
Radi	otherapy specific	<u>.</u>	^			
7.23	Support CYP, Families and carers through the radiotherapy discussion and consent process delivered by the clinical oncologist (radiotherapy consultant)					
7.24	Provide radiotherapy information resource materials for CYP, families and carers about radiotherapy including side effects and actions to take					
7.25	Lead and make autonomous clinical decisions where appropriate in the preparation for and assessment following radiotherapy (See https://www.cclg.org.uk/ACP-capabilities V1.0 pp.18-19 for detailed breakdown)					
Surg	ery specific					
7.26	Demonstrate safe post-operative care following common oncological procedures such as line insertions and removals, biopsies, lumbar puncture and bone marrow biopsy					
7.27	Adjust CYP, families and carers education and discharge planning for post surgery monitoring and reporting, appropriate to recent treatment.					
Imm	notherapy and targeted therapies specific					
7.28	Adjust CYP, families and carers education and discharge planning for post immunotherapy or targeted treatment monitoring and reporting, appropriate to recent treatment					
Bloo	d Product Specific					
7.29	Deliver treatment plans for CYP requiring blood product support, following local policy, and adjust CYP, families and carers education pre, during and post treatment pertinent to blood products					
7.39	Lead and make autonomous clinical decisions where appropriate in the assessment, treatment planning prescribing, managing and monitoring of non-medical authorised blood products.					
	(See https://www.cclg.org.uk/ACP-capabilities V1.0 pp.30-31 for detailed breakdown)					

7.0 Early and Intermediate consequences of SACT, radiotherapy and surgery Understands the consequences of therapies, techniques and modalities used to treat CYP cancer and the appropriate assessment and management of treatment-related adverse effects. Provide relevant and timely information to enable CYP, families and carers to engage in clinical decision-making about their treatment and care	F	Practitioner Level (See Key)		Level of Achievement Required (Benner Taxonomy)	Self Assessment	Lo	e vel Achiev (Assessed)		Evidence of Achievement		
Learning outcomes: Practitioners will be able to:								L	Date	Sig.	
EXAMPLE 7.19 Contribute to the development of policies or guidelines to manage side effects, toxicities and oncological emergencies					V	Proficient	Proficient	E	28.05.22	J Doe	 Identified gap in regional network policies for pregnant staff and safe handling Lit review, discussion with specialist onc pharmacist, gathered evidence from other regions. Led policy review and updates, engaging staff across network Took new policy through Trust guideline review board and network policies approval with regional Trusts Policy implemented and embedded across region with linked education session for staff.
7.1 Identify the most common side effects of SACT, radiotherapy and cancer surgery											
7.2 Explain treatment-related emergencies (including the potential for adverse reactions) and the signs and symptoms											
7.3 Discuss the management of side effects, including neutropenic sepsis, and the impact on CYP, families and carers											
7.4 Identify the evidence to reduce the risk of the acute toxicities of cancer treatments and discuss agents to minimise side effects e.g. antibiotics, antipyretics, analgesics, anti-emetics)											
7.5 Explain the role of supportive care and symptom management during cancer treatment.											

7.6 Understand the emotional and behavioural impact of steroids on children and young people within the whole family dynamic												
7.7 Understand that CYP, families and carers education about signs, symptoms and oncological emergencies must be developed over time, and can discuss how to achieve this.												
Practice Competencies: Practitioners will be able to:							-			0		
Across all modalities of treatment (N.B additional modalities specfic competencies in sections below)												
7.8 Identify patients at increased risk of adverse reactions												
7.9 Identify acute side effects and toxicities of cancer treatments: SACT, radiotherapy, and surgery												
7.10 Use evidence-based interventions to assess, prevent, recognise and assist in the management of emergencies caused by cancer treatment knowing when to refer to, and involve, other healthcare professionals												
7.11 Effectively utilise techniques and tools commonly used to identify deterioration (e.g. PEWS or SPOT, Neuro-Observations)												
7.12 Complete Telephone Triage using the defined helpline (specific competencies detailed in www.cclg.org.uk/triagetool)												
7.13 Locate appropriate policies, treatments and equipment to be used for supportive and emergency care												
7.14 Identify sources of information, provide and use appropriate educational material for CYP, families and carers on how to monitor and report signs of side effects and toxicities of cancer treatments.												

	 	 	 _	 		
7.15 Relate clinical information (regarding side effects) in a way that is appropriate to the CYP, family and carers' understanding						
7.16 Educate CYP, families and carers on the practical skills required for effective treatment and interventions (e.g. use of thermometers, administration of medicines)						
7.17 Demonstrate ability to safely assess CYP, families and carers readiness for discharge and their understanding of side effects, emergencies, when and how to act (specific to their recent treatment modalities). Specifically includes CYP understanding why they should alert a responsible adult if they have symptoms.						
7.18 Show knowledge of blood values and their relevance in the management of side effects						
7.19 Contribute to the development of policies or guidelines to manage side effects, toxicities and oncological emergencies						
7.20 Maintain accurate and contemporaneous records of assessment and management of side effects, toxicities, and emergencies						
Extravastion, hypersensitivity and allergic reactions						
7.21 Recognise signs and symptoms of extravasation, hypersensitivity or allergic reaction						
7.22 Appropriately manage extravasation and infiltration, hypersensitivity or other adverse reaction as per local guidelines						
Radiotherapy specific						
7.23 Support CYP, Families and carers through the radiotherapy discussion and consent process delivered by the clinical oncologist (radiotherapy consultant)						
7.24 Provide radiotherapy information resource materials for CYP, families and carers about radiotherapy including side effects and actions to take						

	·····										
7.25 Lead and make autonomous clinical decisions where appropriate in the preparation for and assessment following radiotherapy (See https://www.cclg.org.uk/ACP-capabilities V1.0 pp.18-19 for detailed breakdown)											
Surgery specific											
7.26 Demonstrate safe post-operative care following common oncological procedures such as line insertions and removals, biopsies, lumbar puncture and bone marrow biopsy											
7.27 Adjust CYP, families and carers education and discharge planning for post surgery monitoring and reporting, appropriate to recent treatment.											
Immunotherapy and targeted therapies specific	· · ·										
7.28 Adjust CYP, families and carers education and discharge planning for post immunotherapy or targeted treatment monitoring and reporting, appropriate to recent treatment											
Blood Product Specific											
7.29 Deliver treatment plans for CYP requiring blood product support, following local policy, and adjust CYP, families and carers education pre, during and post treatment pertinent to blood products											
7.30 Lead and make autonomous clinical decisions where appropriate in the assessment, treatment planning prescribing, managing and monitoring of non-medical authorised blood products. Image: Comparison of the system of th											
Action plan to achieve required competency level:											
Reviewed by Comments:											
Signature and Role:	Date:										
Signature and Role:	Date:										
Signature and Role: Date:											